BEAM Stock Risk & Deep Value Analysis
Beam Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About BEAM Stock
We analyzed Beam Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BEAM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is BEAM Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for BEAM?
- ⚠
Negative or insufficient clinical data for BEAM-101 or other pipeline candidates
- ⚠
Regulatory delays or unexpected safety concerns from health authorities
- ⚠
Competitive breakthroughs from other gene editing companies
- ⚠
Further equity dilution to fund operations if cash burn remains high without partnership revenue
Unlock BEAM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Beam Therapeutics Inc (BEAM) Do?
Market Cap
$2.67B
Sector
Healthcare
Industry
Biotechnology
Employees
509
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit Beam Therapeutics Inc WebsiteIs BEAM Stock Undervalued?
Unlock the full AI analysis for BEAM
Get the complete DVR score, risk analysis, and more
Does BEAM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Beam's moat is primarily built on its foundational IP around base editing and its lead in clinical development for this specific modality. As BEAM-101 progresses, the platform becomes further validated, making it more difficult for competitors to replicate without significant time and capital investment. This could create high switching costs for patients and clinicians once the therapy is established.
Moat Erosion Risks
- •Expiration or invalidation of key patents
- •Emergence of superior or equally effective gene editing technologies
- •Clinical trial failures leading to loss of platform credibility
BEAM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive BEAM Stock Higher?
Near-Term (0-6 months)
- •Further interim data readouts for BEAM-101 in SCD in H2 2026
- •Pipeline updates for BEAM-201 (alpha-1 antitrypsin deficiency) in Q3/Q4 2026
- •Q1 2026 Earnings and Business Update (Estimated early May 2026)
- •Presentation of BEAM-101 data at major medical conferences (e.g., ASH, EHA) in H2 2026
Medium-Term (6-18 months)
- •Initiation of pivotal trials for BEAM-101 (SCD) in late 2027/early 2028
- •Expansion of pipeline with new INDs for additional indications (e.g., in vivo programs)
- •Potential new strategic partnerships leveraging base editing platform
- •Advancement of BEAM-301 (GSD1a) into clinical trials
Long-Term (18+ months)
- •Potential market approval for BEAM-101 (SCD) in the early 2030s, establishing market leadership
- •Broader adoption of base editing as a preferred genetic medicine modality
- •Disruption of existing gene therapy and allogeneic transplant markets for genetic diseases
- •Expansion into larger, more prevalent genetic conditions with in vivo delivery
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for BEAM?
- ✓
Sustained positive clinical data readouts for BEAM-101 and other programs
- ✓
Successful initiation and enrollment of pivotal trials
- ✓
New strategic partnerships or significant non-dilutive funding events
- ✓
Regulatory interactions and milestones
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BEAM (Beam Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
